Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Whole exome sequencing of 45 Lebanese familial breast cancer patients identified four SLX4 coding variants, including one nonsense c.2469G>A (p.Trp823Ter) and three rare missense alleles, together accounting for ~2% of cases, with no clear pathogenic variants replicated in a Spanish cohort of 94 BRCA1/2-negative families (PMID:28202063; PMID:22401137). The paucity of recurrent or segregating variants and absence of multi-family segregation data limit the genetic association.
Functional complementation studies in human SLX4-null fibroblasts demonstrate that the nonsense p.Trp823Ter mutant fails to rescue sensitivity to mitomycin C, camptothecin, and PARP inhibitors, consistent with a loss-of-function mechanism (PMID:23840564). Furthermore, the interaction-defective SLX4(Y546C) allele cannot bind XPF and does not complement interstrand cross-link repair in murine cell models (PMID:26453996). Despite these concordant functional data, the clinical evidence remains limited for SLX4 in hereditary breast carcinoma.
Gene–Disease AssociationLimitedOne nonsense variant in a single proband and rare missense alleles observed without replication or segregation in multiple families (PMID:23840564; PMID:28202063; PMID:22401137) Genetic EvidenceLimitedSingle proband with LoF c.2469G>A (p.Trp823Ter) and absence of confirmed pathogenic variants in larger cohorts (PMID:23840564; PMID:22401137; PMID:28202063) Functional EvidenceModerateLoss-of-function of p.Trp823Ter in cellular rescue assays and disruption of XPF interaction by Y546C demonstrate coherent mechanistic impact (PMID:23840564; PMID:26453996) |